Inogen (NASDAQ:INGN) Issues Quarterly Earnings Results, Beats Estimates By $0.10 EPS

Inogen (NASDAQ:INGN) issued its earnings results on Tuesday. The medical technology company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.36) by $0.10, Zacks reports. Inogen had a negative return on equity of 11.48% and a negative net margin of 6.52%.The business had revenue of $81.72 million for the quarter, compared to the consensus estimate of $82.00 million.

Here are the key takeaways from Inogen’s conference call:

• Returned to Adjusted EBITDA profitability with positive Adjusted EBITDA of $2.7M in 2025, an adjusted net loss narrowed to $8M, and $120.9M in cash with no debt, giving the company financial flexibility to invest and repurchase stock.
• Expanded product portfolio and TAM — launches of Simeox, Voxi 5, and Aurora CPAP masks plus a new patient portal broaden Inogen from a POC company to a multi-product respiratory platform and increase estimated TAM from ~$400M to ~$3.4B.
• Near-term demand/timing issues: several large customer orders shifted from Q4 into H1 2026, U.S. sales declined 5.1% in Q4, rental revenue fell, and gross margin contracted (~220 bps) due to an unfavorable channel mix.
• Share repurchase and forward guidance — Board authorized a $30M buyback and management guided to roughly 6% revenue growth for 2026 with continued positive Adjusted EBITDA and a longer-term goal of ≥10% Adjusted EBITDA within 3–5 years.

Inogen Price Performance

NASDAQ INGN opened at $6.01 on Thursday. The stock has a market capitalization of $163.17 million, a price-to-earnings ratio of -6.99 and a beta of 1.79. Inogen has a 1-year low of $5.34 and a 1-year high of $11.94. The business’s fifty day moving average price is $6.25 and its 200-day moving average price is $7.25.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Inogen in a research report on Monday, December 22nd. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $11.00.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Quarry LP bought a new stake in shares of Inogen during the 4th quarter valued at about $27,000. Prelude Capital Management LLC purchased a new position in shares of Inogen in the third quarter worth approximately $82,000. Corient Private Wealth LLC bought a new stake in Inogen during the fourth quarter valued at approximately $84,000. Integrated Wealth Concepts LLC bought a new stake in Inogen during the first quarter valued at approximately $85,000. Finally, MetLife Investment Management LLC increased its holdings in Inogen by 72.2% during the fourth quarter. MetLife Investment Management LLC now owns 12,699 shares of the medical technology company’s stock valued at $85,000 after buying an additional 5,325 shares during the last quarter. Institutional investors own 89.94% of the company’s stock.

Inogen Company Profile

Inogen, Inc (NASDAQ: INGN) is a medical device company specializing in the development, manufacture and marketing of innovative oxygen therapy solutions. The company’s core focus is on portable oxygen concentrators (POCs) designed to support patients with chronic respiratory conditions such as chronic obstructive pulmonary disease (COPD). Inogen’s offerings aim to provide users with mobility and independence by reducing reliance on traditional compressed-gas cylinders and enabling oxygen therapy on the go.

Inogen’s flagship product line, including the Inogen One family of portable oxygen concentrators, leverages proprietary flow technology to deliver continuous and pulse-dose oxygen.